73
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In designing drug carriers, the drug-to-carrier ratio is an important consideration because using high quantities of carriers can cause toxicity resulting from poor metabolism and elimination of the carriers 1 . However, these issues would be of less concern if both the drug and carrier possess therapeutic effects. (-)-Epigallocatechin-3- O-gallate (EGCG), which is a major ingredient of green tea, has been shown to possess anticancer effects 2- 7 , anti-HIV effects 8 , neuroprotective effects 9 , DNA-protective effects 10 , etc. Here we show that sequential self-assembly of the EGCG derivative with anticancer proteins forms stable micellar nanocomplexes (MNCs), which have greater anticancer effects in vitro and in vivo than the free protein. The MNC is obtained by complexation of oligomerized EGCG with the anticancer protein, Herceptin, to form the core, followed by complexation of poly(ethylene glycol)-EGCG to form the shell. When injected into mice, the Herceptin-loaded MNC showed better tumour selectivity and growth reduction, and longer blood-half-life than free Herceptin.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          The dawning era of polymer therapeutics.

          As we enter the twenty-first century, research at the interface of polymer chemistry and the biomedical sciences has given rise to the first nano-sized (5-100 nm) polymer-based pharmaceuticals, the 'polymer therapeutics'. Polymer therapeutics include rationally designed macromolecular drugs, polymer-drug and polymer-protein conjugates, polymeric micelles containing covalently bound drug, and polyplexes for DNA delivery. The successful clinical application of polymer-protein conjugates, and promising clinical results arising from trials with polymer-anticancer-drug conjugates, bode well for the future design and development of the ever more sophisticated bio-nanotechnologies that are needed to realize the full potential of the post-genomic age.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Polymer conjugates as anticancer nanomedicines.

            The transfer of polymer-protein conjugates into routine clinical use, and the clinical development of polymer-anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A receptor for green tea polyphenol EGCG.

              The major polyphenol in green tea, (-)-epigallocatechin-3-gallate (EGCG), has been shown to prevent carcinogenesis. We have identified a receptor that mediates the anticancer activity of EGCG. Expression of the metastasis-associated 67-kDa laminin receptor confers EGCG responsiveness to cancer cells at physiologically relevant concentrations. Experiments using surface plasmon resonance demonstrate binding of EGCG to the 67-kDa laminin receptor with a nanomolar K (d) value.
                Bookmark

                Author and article information

                Journal
                101283273
                34218
                Nat Nanotechnol
                Nat Nanotechnol
                Nature nanotechnology
                1748-3387
                1748-3395
                27 August 2014
                05 October 2014
                November 2014
                01 May 2015
                : 9
                : 11
                : 907-912
                Affiliations
                [1 ]Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, 138669 Singapore
                [2 ]Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215 USA
                [3 ]Department of Pathology, Kurume University School of Medicine, Kurume University, 67 Asahi-machi, 830-0011 Kurume, Japan
                Author notes
                [* ]Correspondence and requests for materials should be addressed to J.E.C. and M.K. jechung@ 123456ibn.a-star.edu.sg ; mkurisawa@ 123456ibn.a-star.edu.sg
                Article
                NIHMS622929
                10.1038/nnano.2014.208
                4221637
                25282044
                a0df080e-ef67-4c26-af26-beb4ce77d629
                History
                Categories
                Article

                Nanotechnology
                Nanotechnology

                Comments

                Comment on this article